Skip to Content

CLL – The impact of using ibrutinib as front-line treatment

This is the first study to use real-world evidence to describe and compare the time to the next treatment outcomes between ibrutinib and acalabrutinib in patients with treatment-naïve CLL. In this MEDtalk Ryan Jacobs, Atrium Health Levine Cancer Institute, presents the data.

Ryan Jacobs

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top